Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...
Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat ...
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.